Emideltide is a name for DSIP, a nine-residue peptide. FDA’s 2026 assessment distinguishes the free base and acetate; the early rabbit work involved cerebral venous blood dialysate during brain stimulation.

Is emideltide the same as DSIP?

The name refers to the DSIP peptide. It does not make salts, finished products or routes interchangeable. The companion guide distinguishes study exposure from a standard regimen.

Why did the FDA review emideltide in 2026?

The 2026 PCAC review considered nominated forms and uses. The prior meeting record reports 6 yes/7 no/1 abstention on the free base; this is advisory, not a final approval or permission for acetate or every preparation.

What is emideltide used for?

Small sleep studies include favorable IV findings and limited or neutral outcomes. Withdrawal and stress research are investigational and do not establish routine detoxification or a universal insomnia treatment.

Is emideltide legal or FDA-approved?

FDA’s assessment identifies the evaluated forms as not components of approved drugs. A committee vote or absence from one list is not a complete current legal/compounding analysis. Research-use wording is not human-use authorization.

What are the side effects of emideltide?

Small trials and withdrawal reports cannot establish reliable general event rates or long-term safety. An anaesthesia study found heart-rate/EEG changes, so clinical setting and other medicines matter.

Emideltide (DSIP): What It Is and Why the FDA Reviewed It in 2026

By the Peptide Dossier Editorial TeamUpdated October 27, 2026How we source

Emideltide is DSIP: a nine-residue peptide with mixed small human sleep studies and a form-specific 2026 advisory record. Separate evidence, chemical form and route from final FDA approval or compounding permission.

What Is Emideltide?

Emideltide is a name for delta sleep-inducing peptide (DSIP), a nine-residue peptide. FDA’s 2026 assessment distinguishes the free base and acetate. Sharing a peptide sequence does not make salt forms or finished preparations interchangeable. The early rabbit characterization involved cerebral venous blood dialysate during brain stimulation, not simply extraction from the brain of a naturally sleeping animal.

Emideltide vs DSIP: Same Molecule, Two Names

Emideltide and DSIP name the same peptide sequence. The free base, acetate salt and finished nasal or injectable preparation nevertheless require their own specifications and route evidence; a name match does not establish pharmaceutical interchangeability.

The July 2026 FDA Compounding Review

The July 2026 advisory record reviewed for this dossier reports 6 yes, 7 no and 1 abstention on recommending the emideltide free base. That vote is advisory, not a final FDA approval, rule or determination for acetate. The staff assessment separately evaluated the nominated uses and routes. Other peptides’ votes do not establish this product’s evidence, current legal supply or a patient-specific compounding pathway.

How Emideltide Is Thought to Work

Proposed sleep/stress pathways remain unsettled. In 24 women undergoing anaesthesia, DSIP changed heart-rate and EEG measures; this setting cannot establish routine insomnia benefit or universal natural sedation. Short favorable tolerability observations do not establish indefinite safety, freedom from dependence or compatibility with all medicines. These uncertainties are not proof that every exposure is harmful.

What It Has Been Studied For

Sleep findings are mixed. A six-volunteer IV crossover study found a favorable acute sleep signal. A 14-person seven-night insomnia study reported better sleep/daytime function, while a 16-patient controlled trial found weak objective changes and no subjective sleep-quality improvement. These are small disease/IV studies, not proof of a general subcutaneous sleep regimen. Historical withdrawal reports add clinical interest but do not establish a replacement for medically managed alcohol or opioid withdrawal.

Dosage and Sourcing Notes

The assessed research does not establish a universal dose, onset, home reconstitution method, refrigerated shelf life or protective cycle. No source here validates turning a research-use vial into an injectable preparation. A COA or accurate concentration calculation cannot establish sterility, clinical suitability or lawful supply. Product-specific instructions and the actual applicable compounding rules matter; absence from one list is not a complete legal analysis.

Bottom Line

The same peptide name does not erase form, route, study and legal distinctions. Positive small clinical signals and neutral outcomes remain visible without treating an advisory vote as final access permission.